XSTOSPAGO
Market cap5mUSD
Dec 23, Last price
0.19SEK
1D
2.72%
1Q
-26.74%
Jan 2017
-98.59%
IPO
-98.39%
Name
Spago Nanomedical AB (publ)
Chart & Performance
Profile
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,203 14.14% | 1,054 59.70% | 660 92.98% | |||||||
Cost of revenue | 24,486 | 41,828 | 43,790 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (23,283) | (40,774) | (43,130) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 112 | 4 | ||||||||
Tax Rate | ||||||||||
NOPAT | (23,283) | (40,886) | (43,134) | |||||||
Net income | (42,223) 7.41% | (39,309) 0.60% | (39,075) 106.71% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 28,530 | 51,657 | 64,208 | |||||||
BB yield | -89.05% | -122.73% | -31.98% | |||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 191 | 4,725 | ||||||||
Net debt | (45,370) | (62,102) | (52,460) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (44,909) | (38,187) | (35,569) | |||||||
CAPEX | (153) | (3,829) | (4,627) | |||||||
Cash from investing activities | (506) | (3,829) | (4,627) | |||||||
Cash from financing activities | 28,530 | 51,657 | 64,208 | |||||||
FCF | (23,355) | (40,664) | (43,130) | |||||||
Balance | ||||||||||
Cash | 45,217 | 62,101 | 52,460 | |||||||
Long term investments | 153 | 1,000 | ||||||||
Excess cash | 45,310 | 62,049 | 52,427 | |||||||
Stockholders' equity | (229,242) | (59,990) | (70,554) | |||||||
Invested Capital | 270,750 | 257,146 | 255,366 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 97,978 | 66,808 | 41,829 | |||||||
Price | 0.33 -48.10% | 0.63 -86.88% | 4.80 -43.63% | |||||||
Market cap | 32,039 -23.88% | 42,089 -79.04% | 200,780 -18.68% | |||||||
EV | (13,331) | (20,013) | 148,320 | |||||||
EBITDA | (23,002) | (40,418) | (42,754) | |||||||
EV/EBITDA | 0.58 | 0.50 | ||||||||
Interest | 268 | |||||||||
Interest/NOPBT |